Squarepoint Ops LLC Adaptimmune Therapeutics PLC Transaction History

Squarepoint Ops LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $14,364 - $24,623	-10,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $54,648 - $128,251	-31,589 Reduced 74.52%	10,800 $22,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $36,778 - $59,685	10,508 Added 32.96%	42,389 $159,000
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $61,520 - $113,921	17,884 Added 127.77%	31,881 $165,000
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $93,473 - $139,968	-24,216 Reduced 63.37%	13,997 $60,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $85,686 - $119,436	-17,487 Reduced 31.39%	38,213 $203,000
Q4 2020 Feb 16, 2021	SELL	$4.0 - $9.2 $30,340 - $69,782	-7,585 Reduced 11.99%	55,700 $300,000
Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $484,763 - $682,212	63,285 New	63,285 $505,000
Q2 2020 Aug 14, 2020	SELL	$2.58 - $12.1 $32,384 - $151,879	-12,552 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $15,062 - $56,735	12,552 New	12,552 $34,000
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $392,403 - $655,086	-108,100 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.76 - $14.16 $406,456 - $1.53 Million	108,100 New	108,100 $622,000
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $415,154 - $680,712	-50,200 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$10.42 - $13.74 $90,654 - $119,538	8,700 Added 20.96%	50,200 $596,000
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $108,630 - $176,868	15,300 Added 58.4%	41,500 $466,000
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $57,755 - $75,566	8,646 Added 49.25%	26,200 $175,000
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $86,541 - $156,757	17,554	17,554 $144,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.